Benzinga | May 13, 2021 08:01AM EDT

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association

Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that an abstract highlighting positive data from the EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD) has been accepted for oral presentation at EHA2021 Virtual Congress. The annual meeting of the European Hematology Association will be held virtually June 9 -- 17, 2021.